|
Sridhara, R; Eisenberger, M A; Sinibaldi, V J et al. (1998) Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin. Cancer Epidemiol Biomarkers Prev 7:631-4
|
|
Reyno, L M; Egorin, M J; Eisenberger, M A et al. (1995) Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-95
|
|
Sridhara, R; Eisenberger, M A; Sinibaldi, V J et al. (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-53
|
|
Abrams, J S; Eiseman, J L; Melink, T J et al. (1993) Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial. J Immunother Emphasis Tumor Immunol 14:56-64
|
|
Scher, H I; Jodrell, D I; Iversen, J M et al. (1992) Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52:64-70
|
|
Belani, C P; Egorin, M J; Abrams, J S et al. (1989) A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol 7:1896-902
|
|
Conley, B A; Forrest, A; Egorin, M J et al. (1989) Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 49:3436-40
|
|
Tchekmedyian, N S; Kaplan, R S; Eisenberger, M et al. (1987) Phase II study of N-methylformamide in patients with advanced colorectal cancer. Cancer Treat Rep 71:541-2
|
|
Conley, B A; Hornedo, J; Abrams, J et al. (1987) Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 71:861-2
|
|
Belani, C P; Eisenberger, M; Van Echo, D et al. (1987) Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71:1099-100
|
